D-48 | Optimal Duration of Dual Anti-Platelet Therapy after Percutaneous Patent Foramen Ovale and Atrial Septal Defect Closure

The AHA/ASA recommend PFO closure in patients with cryptogenic stroke (CS) and ASD closure for patients with a shunt resulting in RA/RV enlargement. Clinical efficacy and safety for closure has been well documented. Current guidelines suggest 6 months of dual anti-platelet therapy (DAPT) to prevent device thrombosis. However, data on the optimal duration of DAPT post device placement remains sparse.